KYMR
Kymera Therapeutics, Inc.
Stock
$107.39−2.73 (−2.48%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $691M | $848M | $489M | $375M | $407M | $442M | $296M | $92M |
| Current assets | $737M | $871M | $510M | $405M | $419M | $451M | $302M | $93M |
| Total assets | $1.6B | $1.7B | $978M | $576M | $603M | $606M | $487M | $117M |
| Current liabilities | $71M | $83M | $68M | $86M | $71M | $93M | $111M | $35M |
| Total liabilities | $136M | $163M | $142M | $181M | $113M | $146M | $203M | $82M |
| Shareholders' equity | $1.5B | $1.6B | $836M | $395M | $490M | $460M | $284M | −$74M |
| Shares outstanding | 83.2M | 81.6M | 64.9M | 61.1M | 55.2M | 51.7M | 44.8M | — |
| Current ratio | 10.34 | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 | 2.73 | 2.69 |